Ajanta Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Ajanta Pharma's recent management commentary highlights a strong growth trajectory, particularly in its branded generics segment across India and Africa, which is expected to drive high-teen revenue growth for FY27. The company's strategic focus on expanding its Pithampur facility and in-licensing semaglutide positions it well for future growth, despite facing short-term geopolitical headwinds and rising operating expenses. Vista's financial outlook reflects stable revenue growth and improving margins, supported by Ajanta's disciplined R&D spending and a robust pipeline of ANDA filings. The Indian pharmaceutical sector's expansion, coupled with improving pricing power, further enhances Ajanta's competitive position. However, the company must navigate challenges such as price erosion in the US market and geopolitical risks affecting logistics. Over the next 12-24 months, key opportunities include market share gains in chronic therapies and the successful launch of new products, while watchpoints include rising costs and potential supply chain disruptions. Overall, Ajanta Pharma's outlook remains cautiously optimistic, with a focus on sustaining growth and profitability amidst a dynamic market environment
Why We Like This Stock
- Strong growth in branded generics in India and Africa supports high-teen revenue growth expectations
- Strategic investments in capacity expansion and new product launches enhance long-term growth potential
- Improving pricing power in the Indian pharmaceutical sector bolsters Ajanta's competitive position
Things To Watch Out For
- Geopolitical instability may disrupt logistics and increase operating costs
- Price erosion in the US generics market could moderate growth rates
- Rising input costs and regulatory challenges may pressure margins
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 4,209 | 4,648 | 5,453 | 5,992 | 6,852 |
| Profit Before Tax (Cr.) | 1,103 | 1,183 | 1,378 | 1,586 | 1,802 |
| PBT Margin | 26.2% | 25.5% | 2527.0% | 26.5% | 26.3% |
| Net Profit (Cr.) | 808 | 872 | 1,078 | 1,246 | 1,416 |
| Earnings Per Share | 64.3 | 69.5 | 85.9 | 99.3 | 112.8 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| BOB Capital Markets | ▲ Buy | 3,347 | 06-May-2026 |
| Elara Capital | ► Accumulate | 3,115 | 05-May-2026 |
| ICICI Securities | ► Hold | 3,260 | 31-Jul-2026 |
| Jeffries | ▲ Buy | 4,050 | 31-Jul-2026 |
| Motilal Oswal | ▲ Buy | 4,000 | 31-Jul-2026 |
| Prabhudas Liladhar | ▲ Buy | 3,730 | 31-Jul-2026 |
Company Overview
Show Company Profile
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.